3DEXPERIENCE Plateform (c) Dassault Systèmes
Dassault Systèmes, the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, and the French National Institute of Health and Medical Research (Inserm), the only French public research institute to focus entirely on human health and the largest in Europe, today announced the signature of a joint agreement to accelerate clinical research programs by deploying a virtual collaborative platform. The agreement will draw from the expertise of each organization to offer new perspectives for addressing scientific and health challenges of the 21st century.
Inserm will use Dassault Systèmes’ 3DEXPERIENCE platform to conduct its strategic biomedical research programs in the areas of aging, cancer, genomics and microbiota. The platform provides Inserm with an integrated virtual environment for open collaborative research, unified laboratory management and biological and chemical modeling and simulation from Dassault Systèmes’ flagship brand dedicated to scientific excellence, BIOVIA.
In turn, Dassault Systèmes will leverage big data from Inserm’s research programs to calibrate and validate scientific models that can be applied to future technologies for the clinical research domain. These models will enable the company to develop next-generation industry solution experiences targeting clinical trials, to accelerate decision-making and to enable earlier efficacy and safety demonstration with virtual trials.
“We lead long-term, competitive scientific programs in human health and medicine and the Dassault Systèmes’ 3DEXPERIENCE platform will help us support collaboration, project management, data, resources, traceability and other processes”
“At its core, Dassault Systèmes is a scientific company. And at its core, Inserm explores the finest elements of life as we know it—fundamental science. Clinical research has been the catalyst for life-changing discoveries during our lifetime, and introducing capabilities such as modeling and simulation coupled with big data science into translational science, opens up new horizons for investigation,” said Bernard Charlès, President & CEO, Dassault Systèmes. “This fusion of advanced clinical research and the virtual world is a stepping stone to the future of precision medicine and brings us closer to harmonizing product, nature and life.”
For more information on Dassault Systèmes in the life sciences industry, visit http://www.3ds.com/industries/life-sciences/
The respective classifications of the European Patent Office (EPO) and France's National Industrial Property Institute (INPI), which have just published their annual rankings for 2017, have confirmed Inserm's ability to innovate. Inserm placed first among patent applicants in the pharmaceutical sector for ...